slides · global inventory
Compare Peers
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,820
Current window 6,451-6,480
Pages 328
Rows per page 30
Slide function
6,451-6,480 of 9,820
09
The table contrasts clinical outcomes (Hcy levels, lens dislocation, IQ, thrombosis, mortality) between two patient cohorts.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
08
The slide uses a checkmark/cross matrix to highlight AITi's unique positioning across both wealth and asset management segments.AlTi | Investor Presentation Deck | 46 slides · Alvarium Tiedemann
Pitch deck Investor relations Loop · Logic Chain1 hit
21
The slide uses a series of line charts with embedded performance tables to demonstrate alpha generation.AlTi | Investor Presentation Deck | 46 slides · Alvarium Tiedemann
Pitch deck Investor relations 1 hit
07
The table highlights ApolloMed's unique combination of scale, patient coverage, and profitability compared to peers.Apollo Medical Holdings | Investor Presentation Deck | 45 slides · Apollo Medical Holdings
Pitch deck Investor relations 1 hit
24
The chart uses a grouped bar chart format to compare performance metrics across five categories.Apollo Medical Holdings | Investor Presentation Deck | 45 slides · Apollo Medical Holdings
Pitch deck Investor relations Beat · Traction1 hit
15
Includes chemical structure diagrams and multiple bar charts showing dose-response relationships.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
18
The slide uses a matrix-style comparison table to highlight competitive advantages.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
25
The slide uses a checkmark system to highlight specific advantages of RL-007 and a few competitors.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
29
The slide uses a checkmark matrix to highlight the competitive advantage of the company's drug candidate.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
33
The table highlights DMX-1002's unique profile compared to withdrawal support and maintenance therapies.ATAI | Investor Presentation Deck | 36 slides · atai Life Sciences
Pitch deck Investor relations 1 hit
05
The slide uses a simple additive equation visual to represent the growth of the company's CNS portfolio.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
10
The table uses checkmarks to indicate the strength of effect for different GABA-A subtypes (alpha 1, 2, 3, 5).Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Solution1 hit
20
The slide uses a comparison table to frame BAER-101's selectivity profile as a competitive advantage.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
07
Market data as of 9/27/2022.Morgan Stanley | Investment Banking Pitch Book | 13 slides · Morgan Stanley
Regulatory filing Investment bank 1 hit
10
The slide is heavily redacted. It includes a red dashed box highlighting a specific column and a red circle around a cell in that column.Morgan Stanley | Investment Banking Pitch Book | 13 slides · Morgan Stanley
Regulatory filing Investment bank 1 hit
05
The chart shows Orange outperforming the selected peer groups and the S&P 500 index over the specified period.Morgan Stanley | Investment Banking Pitch Book | 30 slides · Morgan Stanley
Consulting deck Investment bank Beat · Problem & ComplicationLoop · Benchmark Gap1 hit
08
Includes management estimates vs street consensus for Orange, compared against two peer groups.Morgan Stanley | Investment Banking Pitch Book | 30 slides · Morgan Stanley
Consulting deck Investment bank Beat · Problem & ComplicationLoop · Benchmark Gap1 hit
24
The slide uses line charts to track valuation trends. Data points represent specific valuation multiples at the end of the period.Morgan Stanley | Investment Banking Pitch Book | 30 slides · Morgan Stanley
Consulting deck Investment bank 1 hit
26
Data as of 9/12/2022. Rule of 40 defined as sum of revenue growth and free cash flow margin.Morgan Stanley | Investment Banking Pitch Book | 30 slides · Morgan Stanley
Consulting deck Investment bank 1 hit
05
The slide uses a visual comparison of vehicle silhouettes to anchor three distinct bar charts representing different performance metrics.Proterra | Investor Presentation Deck | 28 slides · Proterra
Pitch deck Investor relations 1 hit
19
The slide uses donut charts to visualize the split between 3rd party suppliers and vertically integrated manufacturing for specific vehicle types.Proterra | Investor Presentation Deck | 28 slides · Proterra
Pitch deck Investor relations 1 hit
17
The table uses 'X' marks to indicate feature presence and specific clinical trial/dosing status for the Immunovant franchise.Roivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
05
The table uses color coding to distinguish between vaccine strains (green) and non-vaccine strains (blue).SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
05
The slide uses a visual comparison framework to position TRuC-T cells as a superior technological evolution.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
The slide uses a 2x2 layout to present four distinct experimental results supporting the superiority of TRuC technology.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
07
The slide uses a comparative structure to frame gavo-cel as a superior therapeutic option compared to historical anti-mesothelin CAR-T approaches.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
20
The slide presents Kaplan-Meier curves for Progression-Free Survival and Overall Survival alongside a comparative table of historical study data.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations 1 hit
21
The chart uses a grouped bar structure to compare two categories (VMC States vs Other States) across four time periods.Vulcan Materials | Investor Day Presentation Deck | 91 slides · Vulcan Materials Company
Conference presentation Investor relations Beat · Evidence1 hit
43
VMC (Vulcan Materials Company) vs. Peer average (MLM, SUM, EXP, CRH, CX).Vulcan Materials | Investor Day Presentation Deck | 91 slides · Vulcan Materials Company
Conference presentation Investor relations Beat · Development1 hit
62
The slide uses a simple comparison frame to highlight operational efficiency against macroeconomic trends.Vulcan Materials | Investor Day Presentation Deck | 91 slides · Vulcan Materials Company
Conference presentation Investor relations Beat · Resolution1 hit